retatrutide phase 3 trial dosing schedule dose: the complete guide to protocols, titration, and results Starting Phase 3b Clinical Trial

Microdosing tirzepatide engages GLP-1 and GIP pathways at lower doses to support comfort, steady energy, and metabolic stability

The wrong kind of whey protein is notorious for causing bloating and discomfort which is the last thing any GLP-1 user needs

Studies using NMN and NR as oral NAD+ precursors have documented body gains in aged rodents, particularly regarding metabolic health

June 22, 2025

Side effects and how dosing frequency affects them The frequency at which you take GLP-1 oral liquid directly influences which side effects you experience and how severe they are

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC), 2326 October 2023: GLP-1 receptor agonists available evidence not supporting link with thyroid cancer